Mutations of the sigma subunit of the heterotetrameric adaptor-related protein complex 2 (AP2r) impair signalling of the calcium-sensing receptor (CaSR), and cause familial hypocalciuric hypercalcaemia type 3 (FHH3). To date, FHH3-associated AP2r mutations have only been identified at one residue, Arg15. We hypothesized that additional rare AP2r variants may also be associated with altered CaSR function and hypercalcaemia, and sought for these by analysing >111 995 exomes (>60 706 from ExAc and dbSNP, and 51 289 from the Geisinger Health System-Regeneron DiscovEHR dataset, which also contains clinical data). This identified 11 individuals to have 9 non-synonymous AP2r variants (Arg3His, Arg15His (x3), Ala44Thr, Phe52Tyr, Arg61His, Thr112Met, Met117Ile, Glu122Gly and Glu142Lys) with 3 of the 4 individuals who had Arg15His and Met117Ile AP2r variants having mild hypercalcaemia, thereby indicating a prevalence of FHH3-associated AP2r mutations of $7.8 per 100 000 individuals. Structural modelling of the novel eight AP2r variants (Arg3His, Ala44Thr, Phe52Tyr, Arg61His, Thr112Met, Met117Ile, Glu122Gly and Glu142Lys) predicted that the Arg3His, Thr112Met, Glu122Gly and Glu142Lys AP2r variants would disrupt polar contacts within the AP2r subunit or affect the interface between the AP2r and AP2a subunits. Functional analyses of all eight AP2r variants in CaSR-expressing cells demonstrated that the Thr112Met, Met117Ile and Glu142Lys variants, located in the AP2r a4-a5 helical region that forms an interface with AP2a, impaired CaSR-mediated intracellular calcium (Ca 2þ i ) signalling, consistent with a loss of function, and this was rectified by treatment with the CaSR positive allosteric modulator cinacalcet. Thus, our studies demonstrate another potential class of FHH3-causing AP2r mutations located at the AP2r-AP2a interface. † Present address:
Introduction
Familial hypocalciuric hypercalcaemia (FHH) is an autosomal dominant condition characterized by lifelong mild-to-moderate elevations of serum calcium concentrations in association with normal or mildly raised serum parathyroid hormone (PTH) concentrations and low urinary calcium excretion (1, 2) . FHH is genetically heterogeneous and at present comprises three reported subtypes (FHH1-3). FHH1 (OMIM #145980) is due to heterozygous loss-of-function mutations affecting the G-proteincoupled calcium-sensing receptor (CaSR), encoded by the CASR gene, and FHH2 (OMIM #145981) is due to heterozygous loss-offunction mutations of the G-protein alpha-11 subunit (Ga 11 ), encoded by the GNA11 gene (3, 4) . The CaSR and Ga 11 play a critical role in systemic calcium homeostasis by detecting alterations in extracellular calcium (Ca 2þ e ) concentrations and initiating multiple intracellular signalling cascades that include phospholipase-C-mediated accumulation of inositol 1,4,5-trisphosphate (IP 3 ), and increases in intracellular calcium (Ca 2þ i ) concentrations (5, 6) , which in turn leads to decreases in PTH secretion and increases in urinary calcium excretion (7) .
Familial hypocalciuric hypercalcaemia type 3 (FHH3) (OMIM #600740) represents a clinically more severe form of FHH, which may be associated with symptomatic hypercalcaemia, osteoporosis, osteomalacia and cognitive dysfunction (8, 9) . FHH3 is caused by mutations of the adaptor-related protein complex 2 (AP2) sigma subunit (AP2r), encoded by the AP2S1 gene which consists of five exons (Fig. 1) . AP2, which is a ubiquitously expressed heterotetrameric protein comprising a, b, m and r subunits (10) (Supplementary Material, Fig. S1 ), plays a fundamental role in the clathrin-mediated endocytosis of G-protein-coupled receptors (GPCRs) such as the CaSR. The AP2 complex operates as two heterodimers, one comprised of the AP2a and AP2r subunits, and the other the AP2b and AP2m subunits (11) (12) (13) ( Supplementary Material, Fig. S1 ). In the inactive state, the AP2a and AP2b subunits form a diamond-shaped outer complex, and the AP2m and AP2r subunits, are buried within the core of the AP2 complex (10) (11) (12) (14) (15) (16) . Upon activation, AP2a and AP2b bend away from each other, with the AP2r subunit accompanying AP2a and the AP2m subunit being displaced toward the plasma membrane (11, 12, 14) . In this open conformation, the AP2m and AP2r subunits bind to endocytic motifs on transmembrane cargo proteins, and thereby facilitate the association of clathrin with the AP2 complex (12, 14, 17) .
All three FHH3-associated mutations reported to date involve the AP2r Arg15 residue (8, (18) (19) (20) (21) (22) , which is located within the b2-strand (Fig. 2) , and each of the three different missense mutations (Arg15Cys, Arg15His or Arg15Leu) ( Fig. 1) , are postulated to disrupt polar contacts between the AP2r Arg15 residue and the dileucine motif within the intracellular domain of the CaSR, which likely targets it for endocytosis (8, 10, 18) . Indeed, these three FHH3-associated AP2r Arg15 mutations have been shown to alter CaSR cell-surface expression and to have a dominant-negative effect on CaSR-mediated signalling (8, 18) . In contrast, other potential mutations of the AP2r Arg15 residue (Arg15Gly, Arg15Pro or Arg15Ser) have not been observed in humans, and in vitro studies have shown these mutations to impair cell growth (8) . These findings indicate that potential mutations affecting the AP2S1 gene, which is highly conserved in zebrafish, fruitfly and yeast homolog proteins with->99%, >96% and >95% amino acid identity, respectively, may not be commonly observed as they affect cellular viability (13) . Moreover, the large exome and genome datasets contain AP2S1 variants at very low frequencies. For example, examination of the >13 000 alleles from the exome variant server did not reveal the presence of any AP2r variants, whilst the 1000Genomes and Exome Aggregation Consortium (ExAc) databases (23,24) contained only six coding variants, and the dbSNP database had only one AP2r missense variant. The pathophysiological significance of these rare coding AP2r variants is unknown, especially as these large sequencing projects do not contain phenotype information on individuals. Thus, these rare coding AP2r variants may be benign polymorphisms, and we have previously shown that some AP2r variants do not alter CaSR signalling or result in an abnormal phenotype. For example, our in vitro examination of N-ethyl-N-nitrosourea (ENU) induced AP2r variants in mice demonstrated that two missense AP2r variants, Tyr20Asn and Ile123Asn, had no effect on CaSR signalling, and that mice heterozygous for a donor splice-site variant, which results in an in-frame deletion of 17 amino acids, had normal serum and urinary calcium, despite a >50% reduction in AP2r protein expression (25) . This emphasises the need for in vitro and in vivo functional assessments of AP2r variants, in determining their potential role in the pathophysiology of calcium homeostasis.
The DiscovEHR exome sequencing dataset, which has arisen from a collaboration between the Regeneron Genetics Center and Geisinger Health System (26) , offers a new opportunity for studying the role of rare coding variants in human pathophysiology, as the dataset contains matched genotype and phenotype information from 51 289 individuals (26) . We therefore investigated the DiscovEHR dataset, as well as the ExAc and dbSNP datasets, to identify rare coding AP2r variants, and characterized their functional and clinical consequences. These studies demonstrated that AP2r variants located at the interface between the AP2r and AP2a subunits were associated with impaired CaSR signalling and hypercalcaemia.
Results

Identification of two AP2r variants associated with hypercalcaemia in the DiscovEHR exome sequencing dataset
An analysis of the DiscovEHR exome sequencing dataset, which at the time of investigation contained the exomes from 51 289 adult patients (26) , revealed five females to have heterozygous coding AP2S1 variants (Supplementary Material, Table  S1 , Fig. S1 ). Three of these patients harboured the reported FHH3-causing Arg15His mutation located in exon 2 of AP2S1 ( Fig. 1) (18) , and two of these three patients were found to have mild hypercalcaemia ( Table 1) . The other two patients had novel variants which comprised: a heterozygous G-to-A transition at nucleotide c.155, located in exon 3, leading to substitution of the wild-type (WT) phenylalanine (Phe) with the mutant tyrosine (Tyr) at residue 52 of the AP2r protein; and a heterozygous G-to-T transversion at nucleotide c.350, located in exon 5, resulting in a missense substitution of the WT methionine (Met) to a mutant isoleucine (Ile) at residue 117 of the AP2r protein ( Fig. 1 , Supplementary Material, Table S1 ). The novel Phe52Tyr and Met117Ile variants, which were observed only once in the DiscovEHR dataset and were absent in the ExAc dataset, affected evolutionarily conserved AP2r residues (Fig. 1) , and assessments using the SIFT and Polyphen-2 prediction software (27, 28) revealed the following. SIFT predicted that both of these variants would be disease-causing or damaging, whilst Polyphen-2 predicted that Phe52Tyr would be tolerated, but that the Met117Ile was likely to be damaging (Supplementary Material, Table S1 ). The Polyphen-2 predictions were found to be in agreement with the results of the serum calcium concentrations obtained from the Geisinger Health System electronic health records (Table 1) , which revealed that the patient with the Phe52Tyr variant was normocalcaemic, but that the patient harbouring the Met117Ile AP2r variant had mild hypercalcaemia (Table 1) . Thus, these studies reveal that 4 out of 51 289 individuals in the DiscovEHR cohort harboured AP2r variants that were associated with hypercalcaemia and/or FHH3, thereby indicating an overall prevalence of $7.8 per 100 000 for diseasecausing AP2r variants in this cohort.
Identification of six non-synonymous AP2r variants within the ExAc and dbSNP databases
The identification of a non-Arg15 AP2r variant that was associated with a mild elevation of serum calcium concentration ( Fig. 1 and Table 1 ) suggested that additional rare AP2r variants that may disrupt calcium homeostasis may also be present in exome sequence databases. We therefore searched for AP2S1 variants in >60 706 unrelated individuals in the ExAc (24), 1000Genomes (23) and dbSNP datasets (Supplementary Material, Tables S2 and S3 ). This identified 27 AP2r variants, which comprised 6 non-synonymous germline variants and 21 synonymous variants ( Fig. 1 , Supplementary Material, Tables S2  and S3 ). Variants involving the AP2r Arg15 residue were not identified and there were also no nonsense mutations of AP2r. This number of non-synonymous AP2r variants was significantly lower than the expected numbers of missense (n ¼ 63.7) and nonsense (n ¼ 7.8) variants for a protein of 142 amino acids, estimated using the ExAc database (24) (observed AP2r variants vs. expected gene variants: missense ¼ 0.009% vs. 0.1%; and nonsense ¼ 0% vs. 0.01%, v 2 ¼ P < 0.0001). Two of the nonsynonymous AP2r variants were found in exon 2, and consisted of Arg3His (G > A at c.8) and Ala44Thr (C > T at c.130), one nonsynonymous AP2r variant Arg61His (C > T at c.182) was found in exon 3, and the remaining three non-synonymous variants were identified in exon 5, and consisted of Thr112Met (C > T at c.335), Glu122Gly (A > G at c.365) and Glu142Lys (G > A at c.424). All of these six non-synonymous variants, which were observed only once in the ExAc or dbSNP datasets and were not present in the DiscovEHR dataset, affected evolutionarily conserved residues ( Fig. 1B and C) , thereby, indicating they may represent pathogenic mutations rather than benign polymorphisms.
Structural characterization of eight novel AP2r variants
The predicted effects of the eight novel non-synonymous AP2r variants, which comprised two from the DiscovEHR dataset (Phe52Tyr and Met117Ile), five from the ExAc dataset (Arg3His, Arg61His, Thr112Met, Glu122Gly and Glu142Lys) and one from (C) the a4 and a5 helices (residues 107-142) of AP2r-subunit orthologs encoded by AP2S1 exons 2, 3 and 5. Conserved residues are shaded grey. The WT and variant residues are shown in red. The FHH3-associated R15H mutation is shown in blue. The R3, A44, F52, R61, T112, M117, E122 and E142 residues are evolutionarily conserved, thereby indicating that they likely have important structure-function roles in AP2r. dbSNP (Ala44Thr), on the structure of the AP2r protein and their interactions with other subunits within the AP2 complex were characterized (Fig. 2) . The eight AP2r variants were found not to alter the secondary structure of the AP2r a-helical or b-strand structures. Three-dimensional modelling of the AP2r variants was undertaken using the reported crystal structure of the AP2 heterotetramer (12) . The AP2r subunit is comprised of five a-helices and a cluster of five b-strands (12) , and the analysis of three-dimensional modelling, revealed that four of the variants were situated in the b-strand cluster, which is involved in the binding of the AP2r subunit to the cargo protein dileucine motif (10) (Fig. 2) , and the other four variants were located in the a4 and a5 helices, which lie close to the AP2a subunit, that forms a heterodimer with AP2r (11,12) ( Fig. 3 and Supplementary Material, Fig. S1 ). Further analysis of the four variants (Arg3His, Ala44Thr, Phe52Tyr and Arg61His) within the b-strand cluster, revealed that the Arg3His variant, which is located distal to Arg15 in the b1-strand ( Fig. 2B) , would likely disrupt a polar contact between the WT Arg3 residue and the Asp72 residue on the b5-a2 loop (Fig. 2C ), and this would potentially impair stability of the AP2r subunit. However, the Ala44Thr and Phe52Tyr variants, which are located in the a1-b3 loop and the b3-strand of the AP2r subunit, respectively, were not predicted to disrupt intra-or inter-subunit interactions ( Fig. 2D and E), but the Arg61His variant, which is located in the b4-strand and close to the site of the dileucine binding motif of membrane cargo proteins, was predicted to potentially disrupt the binding of AP2r to membrane cargo proteins ( Fig. 2F and G) .
Similar analysis of the four variants (Thr112Met, Met117Ile, Glu122Gly and Glu142Lys) located in the a4-a5 region at the C-terminus of the AP2r protein ( Fig. 2) , revealed that the Thr112Met, Glu122Gly and Glu142Lys variants, would likely disrupt AP2r-AP2a inter-subunit interactions, and thereby impair the structural integrity of this heterodimer and/or activation of mutations affect the Arg15 residue (shown in blue). (B) The AP2r Arg3 residue is located within the b1 strand that lies adjacent to the b2 strand in which the FHH3-associated Arg15 residue is located. Arg3 forms polar contacts with residues Tyr20, Cys70, Asp72 on the adjacent b2-a1 loop, b4-strand and b4-b5 loop, respectively. (C)
Mutation of the Arg3 residue to His3 leads to loss of the polar contact with Asp72, which may disrupt the stability of the r-subunit. (D) The Ala44 residue is located in the a1-b3 loop, and the Phe52 residue is located distal to this, in the b3 strand. Ala44 is not predicted to form polar contacts with any neighbouring residues, while Phe52 is predicted to form polar contacts with the adjacent Phe55 located in the b4 strand. (E) Mutation of the Ala44 and Phe52 residues to Thr44 and Tyr52, respectively, are not predicted to disrupt or form new contacts with other AP2r residues. (F) The Arg61 residue is located in the b4 strand that lies within a cluster of b-strands that converge close to the Arg15 AP2r residue and the dileucine motif binding site (black) of cargo proteins, such as the CaSR and other GPCRs. (G) Mutation of Arg61 to His61 may affect binding to the cargo protein dileucine recognition motif. the AP2 complex ( Fig. 3A-F) . However, the side chain of Met117 and the variant Ile117 face away from the AP2r-AP2a interface, and thus the Met117Ile variant was not predicted to alter interactions with the AP2a subunit, or to disrupt contacts within the AP2r a4-helix ( Fig. 3G and H) . The consequences of all these predicted structural alterations resulting from the AP2r variants, on CaSR-mediated signalling were further assessed ( Fig. 4 and Supplementary Material, Figs S2 and S3 ).
Effects of the eight novel AP2r variants on CaSRmediated signalling and treatment with cinacalcet
To determine the effects of the AP2r variants on CaSR-mediated signalling, HEK293 cells stably expressing the CaSR (HEK-CaSR) were transiently transfected with pBI-CMV4-AP2S1 constructs expressing either the WT or mutant AP2r proteins, as described (8). This bidirectional pBI-CMV4 vector allowed for co-expression of AP2r and red fluorescent protein (RFP) at equivalent levels, as reported previously (8) . The expression of AP2r and RFP was confirmed by fluorescence microscopy and/or western blot analyses (Supplementary Material, Fig. S2A and B ). The expression of AP2r was shown to be similar in cells transiently transfected with WT or variant proteins and higher than the endogenous expression of AP2r ( Supplementary Material, Fig. S2B ). The Ca 2þ e -induced Ca 2þ i responses of HEK-CaSR cells transiently expressing the AP2r variants was assessed using a flow cytometry-based assay, as described (18) . The reported FHH3-causing Arg15His AP2r variant (18) was used as a loss-of-function control in the flow cytometry assays. The Ca 2þ i responses in WT and variant AP2r-expressing cells increased in a dose-dependent manner following exposure to increasing concentrations of Ca 2þ e . However, responses in cells expressing the Thr112Met, Met117Ile or Glu142Lys AP2r variants, which are all located in the a4-a5 helical region of the AP2r subunit ( Fig. 3) , were significantly reduced when compared to WT expressing cells (Fig. 4A-C) , consistent with these AP2r variants leading to loss of CaSR function (18) . Thus, the Thr112Met, Met117Ile and Glu142Lys variants and Arg15His mutant expressing cells showed a rightward shift in the concentration-response curves (Fig. 4A-C) , with significantly increased half-maximal (EC 50 ) values (n ¼ 4-8) of 3.39 mM [95% confidence interval (CI) 3.26-3.53 mM] for Thr112Met expressing cells (P < 0.001), 3.41 mM (95% CI 3.29-3.54 mM) for Met117Ile expressing cells (P < 0.001), 3.63 mM (95% CI 3.49-3.78 mM) for Glu142Lys expressing cells (P < 0.0001) and 3.66 mM (95% CI 3.52-3.81 mM) for Arg15His expressing cells (P < 0.0001), compared to 2.87 mM (95% CI 2.74-3.00 mM) for WT expressing cells (Fig. 4D-F) , In contrast, cells expressing the other five AP2r variants (Arg3His, Ala44Thr, Phe52Tyr, Arg61His and Glu122Gly) had Ca 2þ i responses and EC 50 values that were not significantly different to the WT expressing cells, indicating that they are likely to be benign polymorphisms and not mutations ( Supplementary Material, Fig. S3 ).
We have previously demonstrated that the elevated EC 50 values for CaSR-mediated Ca 2þ i release in cells expressing the FHH3-causing AP2r Arg15 mutations can be rectified by treatment with cinacalcet, which is a CaSR positive allosteric modulator (29) . To investigate whether the loss of function observed in HEK-CaSR cells expressing the AP2r Thr112Met, Met117Ile or Glu142Lys mutations may also be corrected by allosteric modulation, we tested responses in the presence of 10 nM cinacalcet, a dose which normalizes altered signalling responses of the FHH3-causing Arg15 AP2r mutations (29) . Treatment with 10 nM cinacalcet, led to a leftward shift of the abnormal dose-response curves for all three variants ( Fig. 5A-C) , such that the EC 50 values of AP2r variant expressing cells were decreased and similar to values of WT AP2r expressing cells [EC 50 values without cinacalcet (n ¼ 4-8) were 3.51 mM (95% CI 3.37-3.65 mM) for Thr112Met expressing cells (P < 0.001), 3.41 mM (95% CI 3.29-3.54 mM) for Met117Ile expressing cells (P < 0.0001) and 3.55 mM (95% CI 3.40-3.70 mM) for Glu142Lys expressing cells (P < 0.0001); with cinacalcet treatment, EC 50 values (n ¼ 4-8) were 3.01 mM (95% CI 2.87-3.16 mM) for Thr112Met expressing cells [P ¼ not significant (ns)], 2.84 mM (95% CI 2.70-3.00 mM) for Met117Ile expressing cells (P ¼ ns), and 3.04 mM (95% CI 2.94-3.14 mM) for Glu142Lys expressing cells (P ¼ ns), compared to 2.98 mM [(95% CI 2.87-3.10 mM) for WT expressing cells] (Fig. 5D-F ). Thus, cinacalcet is able to correct the loss of function associated with the AP2r a4-a5 helix variants (Thr112Met, Met117Ile and Glu142Lys).
Discussion
Our studies, which have analysed exome datasets from $112 000 individuals for AP2r variants that may cause FHH3 and abnormalities of CaSR-mediated signalling, provide several new insights about: the prevalence of FHH3-associated AP2r mutations, the structural-functional consequences of these mutations; and the importance of the AP2r a4 and a5 helices in mediating activation of the AP2 complex that has a critical role in clathrin-mediated endocytosis of cell-surface proteins such as GPCRs. Thus, our analysis of the DiscovEHR cohort, of adult patients from a stable regional population in Pennsylvania (30) , has provided the first prevalence estimate for FHH3, and found this to be $7.8 cases per 100 000, which is similar to the estimated prevalence of 1-9 cases per 100 000 for FHH1 (31) , and in keeping with FHH being defined as a rare disease (32) . Three out of the five DiscovEHR patients with rare AP2r variants, had the Arg15His AP2r mutation, which has been reported to cause a milder form of hypercalcaemia than the FHH3-causing Arg15Cys and Arg15Leu AP2r mutations (8) . In keeping with this, the Arg15His AP2r mutation in the DiscovEHR cohort was associated with serum calcium concentrations that were mildly elevated, in two patients, or at the upper limit of normal in one patient ( Table 1 ). The two patients with the Arg15His mutation, who were hypercalcaemic, also had vitamin D deficiency and/or chronic kidney disease, and this may have influenced their mild hypercalcaemia ( Table 1 ). In addition, our results reveal that some individuals who are heterozygous for the AP2r Arg15His may be normocalcaemic and this is similar to the reports that heterozygous loss-of-function CaSR mutations, which are associated with hypercalcaemia in the majority of patients may also rarely be associated with normocalcaemia in some individuals (33, 34) . Moreover, our results are the first to report that an AP2r mutation (Met117Ile) that does not involve the Arg15 residue can impair CaSR-mediated signalling (Fig. 4) , and may be associated with hypercalcaemia (Table 1) , consistent with FHH3. Thus, our findings indicate that non-Arg15 AP2r mutations may cause FHH3, and that the current practice of only searching for mutations of the AP2r Arg15 residues in exon 2 will need to be altered to include DNA sequence analysis of the other AP2S1 exons.
Indeed, our demonstration that mutations (e.g. Thr112Met, Met117Ile and Glu142Lys) located in the AP2r a4-a5 helices impair the intracellular calcium signalling responses of CaSRexpressing cells (Fig. 4, Supplementary Material, Table S4 ) indicate the importance of this region for CaSR signalling and/or clathrin-mediated endocytosis. Our structural studies predicted that variations in the AP2r a4-a5 helices would disrupt contacts with the AP2a subunit, and thus are likely to impair AP2 complex formation and/or the conformational changes necessary for AP2 complex activation ( Fig. 3, Supplementary Material ,  Table S4 ). Indeed, in previous studies in which AP2a was deleted in C. elegans, the AP2r homolog was shown to be unstable, whilst the contacts between AP2b and AP2m (which represents the other heterodimer in the AP2 structure) were unaffected (13) . Thus, these previous studies and our investigation of AP2r a4-a5 variants suggest that mutations located at the AP2r-AP2a interface are likely to impair heterodimer function. These studies also indicate that AP2r mutations could be divided into two types: those impairing cargo protein recognition, as is the case for Arg15 mutations; and those impairing AP2 complex activation, as is the case for AP2r a4-a5 mutants. In addition, our in vitro investigations demonstrated that the CaSR-positive allosteric modulator, cinacalcet, can normalize the impaired signalling responses associated with mutations (Thr112Met, Met117Ile and Glu142Lys) of the AP2r a4-a5 helices, and this is similar to our previous report that cinacalcet can rectify the in vitro and in vivo abnormalities of CaSR-mediated signalling associated with AP2r Arg15 mutants (29) . Thus, cinacalcet may have therapeutic potential for patients who have such AP2r mutations located in the a4-a5 helices, together with symptomatic hypercalcaemia or additional clinical phenotypes such as cognitive dysfunction that have been observed in patients with FHH3-causing Arg15 AP2r mutations (8, 29) .
Our findings also highlight the importance of functional characterization of variants identified in large-scale sequencing databases (e.g. ExAc), to assess whether these may represent pathogenic mutations. Thus, population cohorts that contain sequencing data on patients with a range of disorders [including diabetes mellitus type 2, heart disease and inflammatory bowel disease (24) ], should be used with caution as representative of the 'normal' population. Furthermore, in the absence of clinical data, from the ExAc and dbSNP databases, it is difficult to determine whether the carriers within the cohort are unaffected by the disorder under investigation. However, the DiscovEHR cohort, which has available both genetic and clinical data (26) , allows assessment of the pathogenic effect of genetic variants. In addition, our studies illustrate the reliability and difficulties associated with the pathogenicity prediction and threedimensional modelling programs (Supplementary Material, Table S4 ). Thus, the pathogenicity and three-dimensional modelling programs predicted that the AP2r variants Thr112Met and Glu142Lys would likely be deleterious ( Fig. 3 and Supplementary Material, Table S2 ) and that Ala44Thr would likely not be deleterious ( Fig. 2 and Supplementary Material, Table S2 ), and this was found to be in agreement with the in vitro studies that assessed the effects of these variants on CaSRmediated Ca 2þ i signalling ( Fig. 4 and Supplementary Material, Fig. S3 ). However, for other AP2r variants such pathogenicity and three-dimensional modelling programs were not of value when used alone in correctly predicting the effect of the genetic variants. For example, two of the AP2r variants, Arg61His and Glu122Gly, were predicted to be deleterious (Figs 2 and 3 , Supplementary Material, Table S2 ), but were instead found to have no effect on CaSR-mediated Ca 2þ i signalling ( Supplementary  Material, Fig. S3 ); while another, Met117Ile, which was predicted to be likely deleterious by pathogenicity programs (Supplementary Material, Table S1 ) but not three-dimensional modelling (Fig. 3 ) had impaired signalling ( Fig. 4) and was associated with hypercalcaemia in the patient (Table 1 ). Finally, for the Arg3His and Phe52Tyr AP2r variants, the pathogenicity and three-dimensional modelling programs gave different predictions ( Fig. 2 and Supplementary Material, Tables S1 and S2), and both of these were shown by in vitro studies to not result in impaired CaSR signalling ( Supplementary Material, Fig. S3 ), and the Phe52Tyr variant to be associated with normocalcaemia in the patient (Table 1) . Thus, it is important to investigate such genetic variants from large-scale sequencing databases with a range of different methods that include population data combined with clinical information, prediction programs, structural models and in vitro functional studies, to establish variant pathogenicity.
In conclusion, our studies have identified that non-Arg15 AP2r mutations may be associated with impaired CaSRmediated Ca 2þ i signalling and hypercalcaemia, and that such mutations may cluster at the AP2r-AP2a inter-subunit interface, and disrupt formation of the AP2 complex with deleterious effects on CaSR function and Ca 2þ e homeostasis.
Materials and Methods
Ethics statement
All clinical data and unique International Classification of Disease-9 (ICD9) codes for each patient were obtained from the electronic health records (EHR) in a de-identified manner through an approved data broker, in accordance with Institutional Review Board approvals (26, 30) .
DiscovEHR patient cohort
The study cohort has previously been described in detail (26) . In brief, the cohort consisted of Geisinger Health System (GHS) patients within the MyCode Community Health Initiative (26) , and whose germ-line DNA underwent whole exome sequencing. Participants were 59% females and 41% males, with a median age of 61 years, and predominantly White (98%) and were enrolled through primary care and specialty outpatient clinics. Exome sequencing was performed as described previously (26) . Details of sample preparation, sequencing, sequence alignment, variant identification, genotype assignment and quality control steps, including the setting of allele balance at <0.7, high quality combined allele read depth (AD) of !8 reads and per sample genotype quality (GQ) of !30, have been described previously (26) . (36, 37) . AP2r secondary structure was studied using Spider2 (38) . AP2r three-dimensional modelling was undertaken using the reported AP2 structures (Protein Data Bank accession numbers 2XA7 and 2JKR) (10, 12) . Molecular modelling was performed using the PyMOL Molecular Graphics System (Version1.2r3pre, Schrö dinger, LL Pymol) (25) .
Online exome and genome sequencing datasets
Cell culture, constructs and antibodies
Functional assessments of the AP2r variants were performed using HEK293 cells stably expressing the full-length CaSR (HEK-CaSR), as described previously (3, 18) . Cells were maintained in DMEM-Glutamax media (ThermoFisher) with 10% fetal bovine serum (Gibco) and 400mg/mL geneticin (ThermoFisher) at 37 C, 5% CO 2 . Wild-type and mutant pBI-CMV4-AP2S1 expression constructs were generated (using GenBank Accession Number: NM_021575.3), as described (8), and transiently transfected into HEK-CaSR cells using Lipofectamine 2000 (LifeTechnologies). The bidirectional pBI-CMV4 cloning vector was used as it facilitated the co-expression of AP2r and RFP (8) , and site-directed mutagenesis was used to generate the mutant AP2S1 constructs using the Quikchange Lightning Site-directed Mutagenesis kit (Agilent Technologies) and gene-specific primers (SigmaAldrich), as described (39) . The presence of mutations was verified using dideoxynucleotide sequencing with the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies) and an automated detection system (ABI3730 Automated capillary sequencer; Applied Biosystems) (39) . Successful transfection was confirmed by visualizing RFP fluorescence using an Eclipse E400 fluorescence microscope with a Y-FL Epifluorescence attachment and a triband 4,6diamidino-2-phenylindole-FITC-Rhodamine filter, and images captured using a DXM1200C digital camera and NIS Elements software (Nikon) (3, 8, 18) . The expression of AP2r was also determined by western blot analysis using an anti-AP2r antibody (Abcam) and expression of calnexin, used as a control, was determined by western blot analysis using an anti-calnexin antibody (Millipore). The western blots were visualized using an Immuno-Star WesternC kit (BioRad) on a BioRad Chemidoc XRSþ system (3).
Intracellular calcium measurements
The Ca 2þ i responses of HEK-CaSR cells expressing WT or mutant AP2r proteins were assessed by a flow cytometry-based assay, as reported (3, 8, 18) . In brief, HEK-CaSR cells were cultured in T75 flasks and transiently transfected 24 h later with 8mg DNA (3). Forty-eight hours following transfection, the cells were detached, resuspended in Ca 2+ -and Mg 2+ -free Hanks' buffered saline solution (HBSS) and loaded with 1mg/mL Indo-1acetoxymethylester (Indo-1-AM) for 1 h at 37 C. Transfected HEK-CaSR cells were incubated with either a 20% aqueous solution of 2-hydroxypropyl-b-cyclodextrin (Sigma) (vehicle) or 10 nM cinacalcet-HCl (Cambridge Bioscience Ltd.), resuspended in vehicle and added to cells prior to flow cytometry analysis (29) . After the removal of free dye, cells were resuspended in Ca 2þand Mg 2þ -free HBSS and maintained at 37 C. Transfected cells, in suspension, were stimulated by sequentially adding Ca 2þ to the Ca 2þ -and Mg 2þ -free HBSS to increase the [Ca 2þ ] e in a stepwise manner from 0 to 15 mM, and then analysed on a MoFlo modular flow cytometer (Beckman Coulter) by simultaneous measurements of RFP expression (at 525 nm), Ca 2þ i -bound Indo-1-AM (at 410 nm) and free Indo-1-AM (i.e. not bound to Ca 2þ i ) (at 485 nm), using a JDSU Xcyte UV laser (Coherent Radiation), on each cell at each [Ca 2þ ] e , as described (3, 18) . The peak mean fluorescence ratio of the Ca 2þ i transient response after each individual stimulus was measured using Cytomation Summit software (Beckman Coulter), and expressed as a normalized response, as described (3, 18) . Nonlinear regression of concentration-response curves was performed with GraphPad Prism using the normalized response at each [Ca 2þ ] e for each separate experiment for the determination of EC 50 (i.e. [Ca 2þ ] e required for 50% of the maximal response). The mean EC 50 obtained from four to eight separate transfection experiments were used for statistical comparison by using the F-test (3, 8, 18) .
